Ono Pharmaceutical Co., Ltd. ON4.MU Stock
Ono Pharmaceutical Co., Ltd. Price Chart
Ono Pharmaceutical Co., Ltd. ON4.MU Financial and Trading Overview
Ono Pharmaceutical Co., Ltd. stock price | 14.4 EUR |
Previous Close | 17.1 EUR |
Open | 17.1 EUR |
Bid | 17.1 EUR x 0 |
Ask | 18.9 EUR x 0 |
Day's Range | 17.1 - 17.1 EUR |
52 Week Range | 16 - 27.2 EUR |
Volume | 300 EUR |
Avg. Volume | 5 EUR |
Market Cap | 8.64B EUR |
Beta (5Y Monthly) | 0.367816 |
PE Ratio (TTM) | 11.103897 |
EPS (TTM) | 1.61 EUR |
Forward Dividend & Yield | 0.54 (3.18%) |
Ex-Dividend Date | September 28, 2023 |
1y Target Est | N/A |
ON4.MU Valuation Measures
Enterprise Value | -140777652224 EUR |
Trailing P/E | 11.103897 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.019328035 |
Price/Book (mrq) | 0.011256043 |
Enterprise Value/Revenue | -0.315 |
Enterprise Value/EBITDA | -0.883 |
Trading Information
Ono Pharmaceutical Co., Ltd. Stock Price History
Beta (5Y Monthly) | 0.367816 |
52-Week Change | -20.83% |
S&P500 52-Week Change | 20.43% |
52 Week High | 27.2 EUR |
52 Week Low | 16 EUR |
50-Day Moving Average | 17.33 EUR |
200-Day Moving Average | 20.26 EUR |
ON4.MU Share Statistics
Avg. Volume (3 month) | 5 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 488.31M |
Float | 392.92M |
Short Ratio | N/A |
% Held by Insiders | 16.04% |
% Held by Institutions | 43.29% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 70 |
Trailing Annual Dividend Yield | 409.35% |
5 Year Average Dividend Yield | 192.00% |
Payout Ratio | 0.26700002 |
Last Split Factor | 5:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 25.20% |
Operating Margin (ttm) | 31.74% |
Gross Margin | 75.38% |
EBITDA Margin | 35.64% |
Management Effectiveness
Return on Assets (ttm) | 10.94% |
Return on Equity (ttm) | 16.02% |
Income Statement
Revenue (ttm) | 447.19B EUR |
Revenue Per Share (ttm) | 915.8 EUR |
Quarterly Revenue Growth (yoy) | 20.30% |
Gross Profit (ttm) | N/A |
EBITDA | 159.41B EUR |
Net Income Avi to Common (ttm) | 112.72B EUR |
Diluted EPS (ttm) | 1.54 |
Quarterly Earnings Growth (yoy) | 7.29% |
Balance Sheet
Total Cash (mrq) | 164.29B EUR |
Total Cash Per Share (mrq) | 336.43 EUR |
Total Debt (mrq) | 9.17B EUR |
Total Debt/Equity (mrq) | 1.23 EUR |
Current Ratio (mrq) | 2.807 |
Book Value Per Share (mrq) | 1519.184 |
Cash Flow Statement
Operating Cash Flow (ttm) | 159.61B EUR |
Levered Free Cash Flow (ttm) | 131.41B EUR |
Profile of Ono Pharmaceutical Co., Ltd.
Country | Germany |
State | N/A |
City | Osaka |
Address | 8-2, Kyutaromachi 1-chome |
ZIP | 541-8564 |
Phone | 81 6 6263 5670 |
Website | https://www.ono-pharma.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.
Q&A For Ono Pharmaceutical Co., Ltd. Stock
What is a current ON4.MU stock price?
Ono Pharmaceutical Co., Ltd. ON4.MU stock price today per share is 14.4 EUR.
How to purchase Ono Pharmaceutical Co., Ltd. stock?
You can buy ON4.MU shares on the Munich exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ono Pharmaceutical Co., Ltd.?
The stock symbol or ticker of Ono Pharmaceutical Co., Ltd. is ON4.MU.
Which industry does the Ono Pharmaceutical Co., Ltd. company belong to?
The Ono Pharmaceutical Co., Ltd. industry is Drug Manufacturers-General.
How many shares does Ono Pharmaceutical Co., Ltd. have in circulation?
The max supply of Ono Pharmaceutical Co., Ltd. shares is 474.4M.
What is Ono Pharmaceutical Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Ono Pharmaceutical Co., Ltd. PE Ratio is 8.94409900 now.
What was Ono Pharmaceutical Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Ono Pharmaceutical Co., Ltd. EPS is 1.61 EUR over the trailing 12 months.
Which sector does the Ono Pharmaceutical Co., Ltd. company belong to?
The Ono Pharmaceutical Co., Ltd. sector is Healthcare.